Document is current

Article History

Accepted: 6 November 2024

First Online: 15 February 2025

Declarations

:

: AC's institution has received clinical trial funding from Eli Lily, AbbVie, and Rehaler. LS's institution has received clinical trial funding studies funded by AbbVie and Rehaler. GG and RH have received funding for an educational grant from AbbVie (paid to the institution). Over the past 3 years, TSM has had indirect funding to institution for involvement in industry research (site PI) for AbbVie, Ipsen, Rehaler, and Eli Lily; she has educational grants from Abbvie and Amgen. She is on the board of directors for Florida Society of Neurology and was previously on the International Headache Society bord of directors. She is on the editorial board for the Brain and Life Magazine, for the American Migraine Foundation, Confinia Cephalalgica and for Neurology. She is an associate editor for Cephalalgia, Confinia Cephalalgica, and Continuum Audio. She is a deputy editor for Neurology Minute podcast. She has done advisory work for AbbVie, Lundbeck, Pfizer, Teva, LinPharma, eNeura/Aruene, and Merz. Other personal fees are from Medscape, Massachusetts Medical Society, American Headache Society, American Academy of Neurology, Novartis, and Excel Continuing Education. She has been a non-compensated co-author for research for Pfizer, AbbVie and Theranica. TSM has provided unpaid service on the board of directors for the International Headache Society (2021–2023) and currently on the executive board for the Florida Society of Neurology.